Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences, Inc. has reported developments tied to its history as a clinical-stage biopharmaceutical company developing small molecule therapeutics for immune-mediated diseases. Company updates have centered on zetomipzomib, a selective immunoproteasome inhibitor evaluated in autoimmune hepatitis and other chronic immune-mediated diseases, including clinical data presentations and FDA regulatory correspondence.
Other recurring developments include operating and financial results, cost-containment measures, strategic review actions, the completed sale of Sec61-based discovery and development assets including KZR-261 to Enodia Therapeutics, and corporate transaction matters following Aurinia-related acquisition activity and Nasdaq delisting procedures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kezar Life Sciences, a clinical-stage biotechnology company (NASDAQ: KZR), announced the grant of nonqualified stock options to six employees, totaling 232,000 shares at an exercise price of $3.05 per share. This price corresponds to the closing price on April 3, 2023, the grant date. The options, part of an inducement award, will vest over four years, with 25% vesting on the first anniversary of the employee’s start date and the remaining shares vesting monthly. This award complies with Nasdaq Listing Rule 5635(c)(4). Kezar is focused on developing breakthrough treatments for immune-mediated and oncologic disorders, including its lead asset, Zetomipzomib, which has completed a Phase 2 trial for lupus nephritis and KZR-261, a candidate in an ongoing Phase 1 trial for solid tumors.
Kezar Life Sciences reported a net loss of $68.2 million for 2022, compared to $54.6 million in 2021, and a Q4 net loss of $18.2 million. Cash and equivalents stood at $276.6 million as of December 31, 2022, up from $208.4 million in 2021. The company is advancing its zotomipzomib program with the initiation of the PALIZADE Phase 2b trial in lupus nephritis and the PORTOLA trial in autoimmune hepatitis, both set to begin in 2023. Additionally, the KZR-261 Phase 1 trial is currently enrolling its sixth cohort. The increase in research and development expenses reflects investments in these clinical programs, with total R&D costs rising to $51 million in 2022.
Kezar Life Sciences, Inc. (NASDAQ: KZR) has announced the rescheduling of its virtual Research and Development Day to March 15, 2023, at 4:30 PM ET. The event aims to set expectations for 2023 and provide updates on its clinical assets, particularly the advancement of the PALIZADE study for zetomipzomib in lupus nephritis. Additionally, Dr. Craig S. Lammert will discuss autoimmune hepatitis, emphasizing the unmet treatment needs. Following the presentation, a Q&A session will be held. Zetomipzomib is noted for its potential in treating autoimmune disorders without causing immunosuppression.
Kezar Life Sciences (Nasdaq: KZR) has announced a virtual Research and Development Day on March 22, 2023, at 4:30 PM ET. The event will detail the company's pipeline, focusing on zetomipzomib and its development in lupus nephritis, as well as the recently initiated PORTOLA study for autoimmune hepatitis. Key presentations will include insights from experts, such as Craig S. Lammert, M.D. Zetomipzomib, primarily aimed at autoimmune diseases, demonstrated favorable safety in trials. The event will also discuss KZR-261, a novel cancer treatment targeting the protein secretion pathway. Interested parties can register through Kezar's website.